

Supporting Information for

The sustainable synthesis of peptidomimetics via chemoenzymatic tandem oxidation-Ugi reaction

Arleta Madej, Dominik Koszelewski, Daniel Paprocki, Anna Brodzka, Ryszard Ostaszewski

Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland

Synthesis of *N*-(4-methoxybenzyl)formamide:

Reaction conditions: 4-methoxybenzylamine (30 mmol; 3.8 mL) and ethyl formate (12.5 mL) were heated under reflux overnight. After cooling the reaction mixture to room temperature, 5 mL hexane were added. The precipitate was filtered and washed with hexane. Yield 78 % (3.86 g).




Figure 1 ^1H NMR spectrum of *N*-(4-methoxybenzyl)formamide (200 MHz, CDCl_3).

Synthesis of *p*-methoxybenzylisocyanide (5a):

I Method:

Reaction conditions: To a solution of *N*-(4-methoxybenzyl)formamide (16 mmol; 2.64 g) and triethylamine (48 mmol; 6.7 mL) in dry dichloromethane (20 mL) at -78°C phosphoryl oxychloride (20 mmol; 1.85 mL) was added dropwise. After 1 h of stirring at room temperature, the reaction mixture was quenched by adding a saturated solution of NaHCO_3 (20 mL), then extracted with dichloromethane (2×20 mL). The combined organic layers were dried with MgSO_4 and residuals of solvent were distilled under reduced pressure. The crude product was purified by column chromatography on silica gel using hexane/AcOEt (8.5:1.5 v:v) as an eluent. Yield 80 % (1.88 g).

II Method (PTC condition):

Reaction conditions: To a mixture of sodium hydroxide (2.5 g), *t*-butyl ammonium bromide (0.19 g) in distilled water (2.5 mL) was added the solution of 4-methoxybenzylamine (6mmol, 750 μ L) in chloroform (20 mL). After 18 h of stirring at room temperature, the reaction mixture was quenched by adding distilled water, then extracted with dichloromethane (3x20 mL). The combined organic layers were dried with MgSO_4 and residuals of solvent were distilled under reduced pressure. The crude product was purified by column chromatography on silica gel using hexane/AcOEt (8.5:1.5 / v:v) as an eluent. Yield 66 % (582.4 mg).




Figure 2. ^1H NMR spectrum of compound **4a** (200 MHz, CDCl_3).

Appearance of the aqueous Ugi multicomponent reaction samples containing SDS




Figure 3. Photographic images of the Ugi multicomponent reaction samples (reaction with benzyl alcohol **1a** (0.5 mmol), *p*-methoxybenzylamine **3a** (0.5 mmol) and *p*-methoxybenzylisocyanide **5a** (0.5 mmol)) in phosphate buffer 5.2 pH (5 mL), with the addition of SDS, TEMPO and LTV in 25 °C. The reaction was carried out in an open vessel.

- a) suspension of SDS, TEMPO and LTV in phosphate buffer 5.2 pH after 10 minutes of stirring with a magnetic stirrer.
- b) Reaction mixture in suspension of SDS, TEMPO, LTV after addition of **1a**
- c) Reaction mixture in suspension of SDS, TEMPO, LTV and **1a** 10 minutes after addition of **3a** next day.
- d) Reaction mixture in suspension of SDS, TEMPO, LTV and **1a** 10 minutes after addition of **3a**, **4a** and **5a** next day.





Figure 4. ¹H NMR (above) and ¹³C NMR (below) spectra of compounds **6a** N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl-(2-phenylacetyl)amino]-2-phenylacetamide (400 MHz, CDCl₃).

(400 MHz, CDCl₃).




Figure 5. ^1H NMR (above) and ^{13}C NMR (below) spectra of compounds **6b** N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl(2-phenylacetyl)amino]-2-[4-methylphenyl]acetamide (400 MHz, CDCl_3).





Figure 6. ¹H NMR (above) and ¹³C NMR (below) spectra of compounds **6c** N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl-(2-phenylacetyl)amino]-2-[4-methoxyphenyl]acetamide (400 MHz, CDCl₃).





Figure 7. ¹H NMR (above) and ¹³C NMR (below) spectra of compounds **6d** N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl-(2-phenylacetyl)amino]-2-[4-chlorophenyl]acetamide(400 MHz, CDCl₃).




Figure 8. ^1H NMR (above) and ^{13}C NMR (below) spectra of compounds **6e** N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl-(2-phenylacetyl)amino]-2-[4-bromophenyl]acetamide (400 MHz, CDCl_3).





Figure 9. ¹H NMR (above) and ¹³C NMR (below) spectra of compounds **6g** N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl-(2-phenylacetyl)amino]-2-propionamide (400 MHz, CDCl₃).





Figure 11. ¹HNMR (above) and ¹³CNMR (below) spectra of compounds **6j** N-benzyl-2-[(4-methoxyphenyl)methyl]-2-phenylacetamide (400 MHz, CDCl₃).





Figure 12. ¹H NMR (above) and ¹³C NMR (below) spectra of compounds **6k** N-cyclohexyl-2-[(4-methoxyphenyl)methyl]-2-phenylacetamide (400 MHz, CDCl₃).




Figure 13. ¹HNMR (above) and ¹³CNMR (below) spectra of compounds **6l** N-*t*-butyl-2-[(4-methoxyphenyl)methyl-(2-phenylacetylo)amino]-2-phenylacetamide (400 MHz, CDCl₃).




Figure 14. ¹H NMR (above) and ¹³C NMR (below) spectra of compounds **6m** N-*n*-butyl-2-[(4-methoxyphenyl)methyl-(2-phenylacetylo)amino]-2-phenylacetamide (400 MHz, CDCl₃).






Figure 15. ¹H NMR (above) and ¹³C NMR (below) spectra of compounds **6n** N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl-3-(phenylpropionyl)amino]-2-phenylacetamide (400 MHz, CDCl₃).



C




Figure 16. ¹H NMR (above) and ¹³C NMR (below) spectra of compounds **6o** N-benzyl-2-[(4-methoxyphenyl)methyl-4-(phenylprobutyryl)amino]-2-phenylacetamide (400 MHz, CDCl₃).




Figure 17. ^1H NMR (above) and ^{13}C NMR (below) spectra of compounds **6p** N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl-4-(phenylbutyryl)amino]-2-phenylacetamide (400 MHz, CDCl_3).




Figure 18. ¹H NMR (above) and ¹³C NMR (below) spectra of compounds **6r** N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl-4-(phenylpentyl)amino]-2-phenylacetamide (400 MHz, CDCl₃).